Altria

Altria sells cigarettes in the United States and nowhere else. Marlboro is about half the American market. It also sells chewing tobacco, nicotine pouches, cigars and a vape brand, and it owns roughly ten per cent of Anheuser-Busch InBev.

Its central product has been declining for sixty years and will decline for the rest of its existence. There is no version of this analysis in which the volumes go up. Everything else here is a question about how gracefully a business can shrink — and the answer, which surprises most people, is very gracefully indeed.

That is the entire model and it is worth staring at. Between 2016 and 2025 Altria's revenue rose four per cent — essentially nothing. Its operating income rose thirty-seven per cent. Its operating margin went from 45.3% to 59.8%. And its share count fell fourteen per cent. Fewer cigarettes, higher price, lower cost, fewer owners.

The mechanism is price. A smoker who has smoked Marlboro for thirty years does not switch brands because the price went up forty cents. Nicotine is the most reliable customer-retention technology ever commercialised, and it allows Altria to raise prices faster than it loses volume, every year, almost regardless of the economy. That is why revenue stays flat while unit sales fall — and why the margin expands, because the extra price arrives with no extra cost attached.

The result is one of the most extraordinary profit profiles in public markets:

Put Altria through a screen and you get some of the most alarming numbers we have encountered.

Shareholders' equity is an accounting residue: assets minus liabilities. It records what owners put in, plus profits kept, minus what has been paid out. It has nothing to say about what a business is worth.

Altria's equity has gone from +$2.8 billion in 2020 to −$3.5 billion in 2025 for a simple reason: over decades it has returned more cash to shareholders — through dividends and buybacks — than the accountants ever recorded as capital contributed. It bought back stock at prices far above book value, and every such purchase reduces the equity line by the cash paid.

★ Negative book value at a company like this is not a hole. It is a receipt. It is the arithmetic trace of a business that has given away more than it was ever formally given, which is precisely what a mature cash machine is supposed to do. The number that matters is whether the cash keeps coming — $9.07 billion of it last year — and whether the debt is serviceable, which at 1.89 times EBITDA and ten times interest cover it plainly is.

This is the mirror image of two companies we published this week. At Chubb, price-to-book is the single best measure available. At S&P Global, it is meaningless because the valuable assets were built rather than bought. Here it is meaningless for the opposite reason again — the equity has been given away. ★ Three companies, three reasons the same ratio fails or works. That is the whole point of this series.

An investment in Altria is a single arithmetic bet: can price rises outrun volume declines for long enough to justify the price you pay? Everything else — the pouches, the vapes, the beer stake — is a footnote against that.

So the volume line is the one to watch, and the recent news is better than the reputation.

Why have the declines moderated? Management's explanation is specific and, we think, credible: reduced cross-category movement to illicit e-vapor products. For several years, unauthorised flavoured vapes — largely imported, largely unregulated — were pulling smokers out of the legal cigarette market faster than the underlying quit rate. Enforcement has tightened. Those smokers have partly come back.

★ That is a genuinely important nuance and it cuts both ways. It means part of the recent improvement is a regulatory windfall rather than a change in smoking behaviour — and regulatory windfalls reverse. But it also means the underlying decline rate was never as bad as the reported numbers suggested; some of it was leakage to a black market rather than people giving up.

Meanwhile the category that is growing is one Altria barely participates in. Nicotine pouches — the small white sachets — are now 59.9% of the entire US oral tobacco category, up 8.1 percentage points in a year. That market is dominated by Zyn, which belongs to Philip Morris International. Altria's answer, on! and the newer On+, has just reached 120,000 stores and gained 0.8 points of retail share sequentially.

★ Gaining share in the fastest-growing nicotine category is genuinely the right thing to be doing. It is also starting from a long way behind, in a category where the leader established itself first and the switching costs are low.

Everything above describes a well-run declining business. This part describes the other thing, and it is why we scored management a four.

Fifteen and a half billion dollars spent on the future of nicotine, and the current position is a near-total write-off plus a product barred from the market by a court. There is no charitable reading of that sequence. It is the single strongest argument against paying up for this company, and it is not in any ratio on the screen.

What we would say in mitigation, because it is true. Altria has been a good steward of the core: the margin expansion in Part I is real and it is the product of pricing discipline and cost control that many companies could not manage. It has reduced net debt. It has sold down part of its Anheuser-Busch InBev stake — about 197 million shares, roughly 10% of that company — to fund buybacks rather than borrowing for them. And it retired 14.1% of its own shares over nine years.

But the pattern is clear and an investor should price it. When this company has cash it cannot deploy in cigarettes, it has repeatedly bought expensive positions in adjacent nicotine businesses at the top of their hype cycles and lost the money. ★ The right conclusion is not that management is incompetent — the core business is superbly run. It is that the cash should come to shareholders rather than be reinvested, and the 76.7% of free cash flow paid out as dividends suggests the board has largely accepted this.

This is why people own Altria, so we will be precise — and there is a piece of news here that our data pull had not caught.

★ On 27 August 2026 — one day before the closing price used in this analysis — Altria raised its quarterly dividend from $1.06 to $1.11, an increase of 4.7%. The new annualised rate is $4.44 and the yield at $68.65 is 6.47%. It was the 61st increase in 57 years.

And note the direction, because it is the opposite of what we have found everywhere else this month.

★ Four years of gentle deceleration, and then an acceleration. We have spent this month documenting the opposite pattern — Zoetis from 15% to 6% five months before cutting guidance, Rexford from 31% to 1.2%, T. Rowe Price from 11% to 2.4%, S&P Global to 1.0%. Here the board did the reverse, in the same month that volume declines moderated for a fourth quarter. We read that as a genuine statement of confidence, and it is the most encouraging single fact in this analysis.

What would force a cut. Free cash flow would have to fall roughly 25% and stay there. Given that revenue has moved four per cent in nine years and the margin has only ever expanded, that requires either a step-change in the volume decline — a national menthol ban, a punitive federal excise increase, or a genuine collapse in smoking prevalence — or an adverse litigation outcome large enough to matter.

★ None of those is fanciful, and all of them are slow. A 6.47% yield covered 1.12 times, with a payout the company deliberately targets at 80% and a record of 61 increases in 57 years, is about as reliable a high yield as public markets offer. It is also, unmistakably, a high-payout instrument with a thin reserve, and it should be sized accordingly.

We wrote about British American Tobacco on 2 July and called it income with eyes open. Anyone considering one should understand how it differs from the other, because the two are commonly treated as interchangeable and are not.

The trade is diversification against margin. Altria is a concentrated bet on one product in one country, with the best economics in the industry and a yield more than a point higher. British American is spread across the world, which insulates it from any single regulator, and carries the goodwill of an acquisition spree instead.

Which is better depends on what you are afraid of. If your fear is American regulation — a federal menthol ban, a nicotine cap, a punitive excise — Altria has nowhere to hide and BTI does. If your fear is that a large acquisition-built balance sheet eventually has to be written down, the reverse applies.

★ What they share is the thing that matters most: both are melting ice cubes that pay you very well while they melt, and the entire question in each case is whether the yield plus the buyback exceeds the rate of melt. At Altria that arithmetic is 6.47% of income plus roughly 1.5% of annual share count reduction, against a business whose profits are still growing at three to five per cent. It works. It simply does not compound.

So what does 12.1 times assume? It assumes volumes keep falling at something like the current rate rather than accelerating, that pricing power holds, that no federal ban arrives, and that adjusted earnings grow at the three to five per cent the company is guiding to. That is a description of the recent past extended forward — which is the right base case, and also exactly what a value trap looks like from the inside.

★ Here is the arithmetic that decides it. A 6.47% yield, plus a share count shrinking roughly 1.5% a year, plus adjusted earnings growing three to five per cent, gives you something in the region of nine to eleven per cent a year — provided nothing breaks. That is a perfectly good return from a business that is unquestionably dying. The whole judgement is how much you are willing to pay for a stream you know has an end.